

Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews

W Darlene Reid^{1,2}
Cristiane Yamabayashi¹
Donna Goodridge³
Frank Chung⁴
Michael A Hunt¹
Darcy D Marciniuk⁵
Dina Brooks⁶
Yi-Wen Chen¹
Alison M Hoens^{1,7}
Pat G Camp^{1,2}

¹Department of Physical Therapy, University of British Columbia, Vancouver, ²Institute of Heart and Lung Health, University of British Columbia, Vancouver, ³College of Nursing, University of Saskatchewan, ⁴Physiotherapy, Burnaby Hospital, Fraser Health, British Columbia, ⁵Division of Respiriology, Critical Care and Sleep Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, ⁶Department of Physical Therapy, University of Toronto, Toronto, ON, ⁷Providence Health Care, Vancouver, BC, Canada

Correspondence: W Darlene Reid
Muscle Biophysics Laboratory,
Rm 617-828 West 10th Avenue,
Vancouver, BC V5Z 1M9, Canada
Tel +1 604 875 4111 ext 66056
Fax +1 604 822 1870
Email darlene.reid@ubc.ca

Introduction: The prescription of physical activity for hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) can be complicated by the presence of comorbidities. The current research aimed to synthesize the relevant literature on the benefits of exercise for people with multimorbidities who experience an AECOPD, and ask: What are the parameters and outcomes of exercise in AECOPD and in conditions that are common comorbidities as reported by systematic reviews (SRs)?

Methods: An SR was performed using the Cochrane Collaboration protocol. Nine electronic databases were searched up to July 2011. Articles were included if they (1) described participants with AECOPD, chronic obstructive pulmonary disease (COPD), or one of eleven common comorbidities, (2) were an SR, (3) examined aerobic training (AT), resistance training (RT), balance training (BT), or a combination thereof, (4) included at least one outcome of fitness, and (5) compared exercise training versus control/sham.

Results: This synthesis examined 58 SRs of exercise training in people with AECOPD, COPD, or eleven chronic conditions commonly associated with COPD. Meta-analyses of endurance (aerobic or exercise capacity, 6-minute walk distance – 6MWD) were shown to significantly improve in most conditions (except osteoarthritis, osteoporosis, and depression), whereas strength was shown to improve in five of the 13 conditions searched: COPD, older adults, heart failure, ischemic heart disease, and diabetes. Several studies of different conditions also reported improvements in quality of life, function, and control or prevention outcomes. Meta-analyses also demonstrate that exercise training decreases the risk of mortality in older adults, and those with COPD or ischemic heart disease. The most common types of training were AT and RT. BT and functional training were commonly applied in older adults. The quality of the SRs for most conditions was moderate to excellent (>65%) as evaluated by AMSTAR scores.

Conclusion: In summary, this synthesis showed evidence of significant benefits from exercise training in AECOPD, COPD, and conditions that are common comorbidities. A broader approach to exercise and activity prescription in pulmonary rehabilitation may induce therapeutic benefits to ameliorate clinical sequelae associated with AECOPD and comorbidities such as the inclusion of BT and functional training.

Keywords: pulmonary disease, chronic obstructive, comorbidity, exercise, physical fitness

Introduction

Chronic obstructive pulmonary disease (COPD) is the fifth leading cause of death in the world and the mortality rate is expected to increase more than 30% during the next 10 years.¹ Acute exacerbations of COPD (AECOPD) are common and are a key predictor of increased morbidity, health care costs, and mortality. The Global Initiative for Lung Disease (GOLD)¹ defines a COPD exacerbation as “an event in

the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum that is beyond normal day-to-day variation, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD". Most patients with COPD have at least one exacerbation per year; a substantial proportion of patients (17%) have three or more episodes per year.^{2,3}

Many exacerbations of COPD are managed on an outpatient basis, but if the patient is hospitalized, the length of stay (LOS) is prolonged: the median LOS in Canadian hospitals is 13 days,⁴ which translates to an estimated cost of CAD\$9500 per hospitalization.⁵ Premature discharge resulting in shorter LOS, however, is associated with increased readmission and mortality.⁶

Hospitalization to treat acute illness can have a detrimental effect on muscle performance.⁷ Muscle impairment and functional decline have been well-documented in older hospitalized patients, and have been attributed to the consequences of hospitalization rather than the admitting illness.^{8–11} In a previous study on 1181 hospitalized patients with acute medical illnesses (circulatory, 27%; respiratory, 20%; gastrointestinal, 15%; cancer, 6%), 17% of patients required assistance with mobility on discharge, despite being able to walk independently prior to admission.¹² Pitta et al reported that patients who are hospitalized with an acute exacerbation of COPD spend the majority of their time sitting, and do not return to their baseline level of activity even after 1 month post-discharge.¹³

Caring for hospitalized patients with AECOPD can be complicated by the presence of other chronic conditions, which can also influence the severity of the exacerbation and the health outcomes of the patient. Individuals with COPD have a higher risk of multimorbidity^{14–27} (Table 1) than individuals with other chronic illnesses. Despite this, there has been widespread failure to address the complexities inherent in living with multiple chronic illnesses simultaneously,

especially in the hospitalized, acutely ill population. Devising exercise plans for hospitalized AECOPD patients living with multimorbidity is complicated by the limitations imposed by the acute exacerbation and by the synergistic effect of the multiple conditions upon the person. While recent reviews have examined evidence regarding the effectiveness of exercise therapy for people with multimorbidity in community settings,^{28,29} none have focused on hospitalized patients with COPD who also experience multi-morbidity. National physical activity guidelines fail to address this issue as well.^{30,31}

Systematic reviews (SRs) provide a high level of evidence regarding the efficacy of therapeutic intervention, but the sheer number of available SRs on a given topic can make it difficult for the clinician to distill the important messages. Systematic reviews of systematic reviews have been purported as a way to both evaluate and summarize the key messages on important therapies, and are commonly published in areas of health care.^{32–36} The aim of the current research was to synthesize the relevant literature on the benefits of exercise for people with multimorbidity who are experiencing an AECOPD. Thus we posed the question: What are the parameters and outcomes of exercise in AECOPD and in commonly associated comorbidities as reported by SRs?

Methods

Search strategy

A systematic review was performed using the methodology outlined by the Cochrane Collaboration protocol.³⁷ Electronic databases were searched up to July 2011 including the Cochrane Controlled Trials Register, Cochrane-Systematic Reviews, MEDLINE, CINAHL (Cumulative Index to Nursing and Allied Health Literature), SPORTDiscus, EMBASE, PEDro (Physiotherapy Evidence Database), PsycINFO, and EBM reviews. Gray literature and reference lists from relevant articles were also reviewed to identify additional articles. Search terms were exemplified by the

Table 1 Prevalence of chronic diseases in the population and in people with COPD

Chronic disease	Prevalence in population	Prevalence in COPD
Heart failure	<1% age 50–59; ~7% age 80–89 ²²	20% ²⁴
Ischemic heart disease	5%	Severe and very severe COPD two-fold risk ²⁵
Peripheral arterial disease	4.3% at age 40, 14.5% at age 70 ²⁰	Smokers OR 4.46 ²⁰
Hypertension	15%; ~50% ≥50 years ¹⁸	1.6-fold risk ²⁵
Obesity	67% over age 30 ¹⁴	54% ²⁶
OA	13% at age 50; ~40% at age 75 ²³	
Osteoporosis/osteopenia	15% over age 50 ²¹	60%–70% ²⁷
Diabetes mellitus – type 2	2.8% in 2000; 6.4% in 2010 with a 10.2% in the Western Pacific ¹⁶	Increased relative risk 1.5–1.8 ²⁵
Depression	4.7% persistent depression or anxiety ¹⁷	Depressive symptoms: 10%–80% ²⁵ Depression that requires treatment: 19%–42% ²⁵

MEDLINE search strategy (Appendix 1) and were modified accordingly to fit the requirements of the other databases.

Study criteria

Articles were included if they (1) described participants with AECOPD or COPD, or had one or more of the following conditions that are common comorbidities: anxiety/depression, atherosclerosis, ischemic heart disease, peripheral vascular disease, heart failure, hypertension, diabetes mellitus, human immunodeficiency virus (HIV/AIDS), osteoarthritis (OA), osteoporosis, obesity/overweight, or older adults; (2) were SRs that included at least one randomized controlled trial (RCT); (3) examined an exercise intervention of aerobic training (AT), resistance training (RT), balance training (BT), or a combination thereof; (4) included at least one outcome of fitness; (5) had comparison groups of exercise training versus control/sham (that consisted of usual treatment, no exercise, or attention placebo); (6) were published in English. Articles were excluded if they (1) were published before 2000, or (2) investigated tai chi, yoga, or qi gong due to the multiple forms of these exercises and the difficulty in defining the expected training response to fitness outcomes. If two SRs reported on the same question and the majority of papers included were the same, only the SR with more articles and a more comprehensive review was included. Also, several

SRs did not contain meta-analyses. These were reviewed if they met the criteria above, but data were extracted only if other reviews with meta-analyses were not available on the outcomes of interest.

Two individuals independently screened all titles and abstracts retrieved. Any discrepancies were discussed and resolved. From the selected abstracts, one person screened 362 full text articles to determine if they met the inclusion criteria using a screening form. A second person was consulted to confirm agreement on all articles to be excluded. The flow chart of the search strategy and study selection is summarized in Figure 1.

For each condition, one of the coauthors abstracted data and performed the quality assessment, which was double-checked by at least one person. All discrepancies were discussed and reconciled. Data abstracted, when available, included (1) condition, age, and gender of participants, (2) the modality (Mo), frequency (Fr), intensity (I), time of session (T), and duration of program (D) of the exercise intervention, (3) descriptors of the control, placebo, or sham group, and (4) outcomes of fitness, disease control or prevention, quality of life, and function.

Data related to functional training was abstracted. Functional training can be defined as mobility exercises that are functionally- or task-based rather than focused on strength




Figure 1 Flow chart of retrieval, screening and inclusion of systematic reviews.

training of particular muscle groups or endurance training to improve cardiovascular or aerobic status. Examples are stair climbing, repetitive sit to stand, and transfers. Such training often includes a combination of strength, endurance, and balance.

Quality assessment

All SRs were assessed using the AMSTAR quality assessment tool.³⁸ Scores for each item and totals are reported. Item 11 was scored as “yes” if the conflict of interest was stated for the authors of the SR.

Data synthesis

Data was synthesized in tables that described the study quality (Table 2), the participants and interventions (Table 3), and outcomes (Table 4). An outcome was assigned to one of two categories based on whether it was measured in several conditions or if it was applied to evaluate a disease specific marker: (1) generic fitness (eg, exercise capacity, strength), quality of life, and functional outcomes (eg, timed up-and-go test, stair climbing), and (2) disease specific fitness, control, and prevention outcomes (eg, dyspnea, mortality, pain, ejection fraction, cholesterol levels).

Only statistically significant outcomes are reported in Table 4. When available, quantitative data for each meta-analysis was described including the number of studies, the number of participants, the standardized effect size or weighted mean difference, risk ratio, odds ratio, and 95% confidence intervals. If this information was not available, an attempt was made to determine the number of studies that reported a significantly positive change versus the total number of studies that measured the outcome. Nonsignificant findings or trends are not reported.

Results

Study selection

A search of the eight databases yielded 3276 citations and abstracts after duplicates were removed. After independent screening of the citations by two reviewers, 362 full-text articles were selected and reviewed for inclusion. Fifteen additional articles were identified from manual searching of reference lists. The main reasons for excluding articles were that they were not an SR, that participants did not have COPD/AECOPD or one of the other conditions of the search strategy, there was no exercise intervention, the exercise intervention was not clearly described or not differentiated from concurrent treatment, there was no comparison between an exercise group and a control group, the SR reported on

similar data but had few articles, the article was not available in English, or the article was published before 2000. No SRs were identified that compared exercise to a control group in people with asthma or bronchiectasis. Fifty-eight SRs met the inclusion criteria.

Quality assessment

The number of RCTs in any of the SRs that related to our question ranged from 4 to 83. The average AMSTAR score was 7.5 out of a potential 11. The most common items not reported were a list of excluded articles (only 26% of SRs provided this list), an examination of publication bias (ie, funnel plot or Egger regression test, which 45% reported), a statement regarding conflict of interest (50% reported), a selection and abstraction of data performed by two reviewers (65% reported), and a search of the gray literature (59% reported). All other items were addressed by $\geq 71\%$ of the SRs.

Characteristics of participants

The age of participants ranged between 18 years and the “very elderly”. SRs that described people with HIV or depression had the youngest participants. Gender varied from 100% male to 100% female. SRs that described older adults had the largest sample sizes.

Characteristics of interventions and outcomes in the different chronic conditions

Characteristics of the interventions are detailed in Table 3, while outcomes in the different chronic conditions are shown in Table 4.

AECOPD

One SR investigated the benefits of aerobic and resistance training in people with COPD (AMSTAR of 11).³⁹ Aerobic and resistance training of the extremities improved walk distance performance and quality of life measures in addition to decreasing dyspnea, compared to the control group. Exercise also reduced admissions to hospital and mortality as demonstrated by meta-analyses of five and three RCTs, respectively.³⁹ The SR included studies that initiated exercise immediately after or up to 6 weeks after treatment initiation for AECOPD as part of pulmonary rehabilitation on an out- or in-patient basis. Frequency of training ranged from three times a week to twice daily. The intensity of aerobic training was not reported.

COPD (stable)

Six SRs investigated the benefits of AT and RT in people with COPD, and the AMSTAR scores ranged between 5 and 10.^{40–45}

Table 2 AMSTAR score

Condition	Author	AMSTAR scores											Total
		1	2	3	4	5	6	7	8	9	10	11	
AECOPD	Puhan et al ³⁹	1	1	1	1	1	1	1	1	1	1	1	11
Chronic obstructive pulmonary disease	Lacasse et al ⁴²	1	1	1	1	1	1	1	1	1	0	1	10
	O'Shea et al ⁴³	1	1	1	0	0	1	1	1	1	0	1	8
	Salman et al ⁴⁴	1	0	1	1	0	1	1	1	1	1	0	8
	Chavannes et al ⁴⁰	1	0	1	1	0	1	0	0	1	0	0	5
	Vieira et al ⁴⁵	1	0	1	1	0	1	1	1	0	0	0	6
Older adults	Janaudis-Ferreira et al ⁴¹	1	0	1	1	0	1	1	0	0	0	0	5
	Liu and Latham ⁵⁰	1	1	1	1	1	1	1	1	1	1	1	11
	Howe et al ⁴⁹	1	1	1	1	1	1	1	1	1	0	1	10
	Gillespie et al ⁴⁸	1	1	1	1	1	1	1	1	1	1	1	11
	Weening-Dijksterhuis et al ⁵²	1	0	1	1	0	1	1	1	0	1	1	8
Heart failure	Forster et al ⁴⁷	1	1	1	1	0	0	0	0	0	1	1	5
	Chin et al ⁴⁶	1	1	1	1	0	1	1	1	0	0	1	8
	Rydwik et al ⁵¹	1	0	1	1	0	1	1	1	0	0	0	6
	Davies et al ⁵⁵	1	0	1	0	0	0	1	1	1	1	1	7
	Hwang et al ⁵⁴	1	1	1	0	0	1	1	1	1	1	0	8
	Hwang and Marwick ⁵⁷	1	0	1	0	0	1	0	0	0	0	0	3
	Chien et al ⁵³	1	1	1	1	0	1	1	0	1	0	0	7
	Haykowsky et al ⁵⁶	1	1	1	1	0	1	1	1	0	1	0	8
	van Tol et al ⁵⁸	1	1	1	0	0	0	1	1	1	1	0	7
	Spruit et al ⁶¹	1	1	1	0	0	1	1	1	0	0	0	6
Ischemic heart disease	Cahalin et al ⁶⁰	1	0	0	0	0	1	0	0	0	0	0	2
	Benton ⁵⁹	1	0	0	0	0	1	0	0	0	0	0	2
	Haykowsky et al ⁶⁵	1	1	1	0	0	1	1	1	1	0	1	8
	Valkeinen et al ⁶⁸	1	0	0	0	0	1	1	0	1	1	0	5
	Cortes et al ⁶⁴	1	1	1	1	0	1	1	1	1	0	1	9
	Jolliffe et al ⁶⁶	1	1	1	0	1	1	1	1	1	1	1	10
	Clark et al ⁶²	1	1	1	0	0	1	1	1	1	1	1	9
	Cornish et al ⁶³	1	0	1	0	0	1	0	0	0	0	0	3
	Oliveira et al ⁶⁷	1	0	1	0	0	1	0	0	0	0	0	3
	PVD	Watson et al ⁶⁹	1	1	1	0	1	1	1	1	1	0	1
Hypertension	Wind and Koelemay ⁷⁰	1	1	1	0	0	0	1	1	1	1	0	7
	Dickinson et al ⁷³	1	1	1	0	1	0	1	1	1	1	0	8
Obesity	Cornelissen and Fagard ⁷²	1	1	0	0	0	0	0	0	1	1	0	4
	Whelton et al ⁷⁴	1	1	1	0	1	1	0	0	1	1	1	8
	Kelley et al ⁷¹	1	1	1	1	0	0	1	0	1	1	0	7
Osteoarthritis	Shaw et al ⁷⁶	1	1	1	1	1	1	1	1	1	1	1	11
	Witham and Avenell ⁷⁵	1	1	1	0	0	1	1	0	1	1	1	8
	Devos-Comby et al ⁷⁹	1	0	1	1	0	1	1	1	1	1	0	8
	Lange et al ⁸⁰	1	1	1	0	0	1	1	1	1	0	0	7
	Ottawa Panel ⁷⁷	1	1	1	1	1	1	1	1	0	0	0	8
Osteoporosis	Brosseau et al ⁷⁸	1	1	1	1	0	1	1	1	0	0	0	7
	Pelland et al ⁸¹	1	1	1	1	1	1	1	1	1	0	0	9
	Li et al ⁸³	1	0	1	0	0	0	1	1	1	0	1	6
	de Kam et al ⁸²	1	0	1	1	0	1	1	1	0	0	1	7
Diabetes mellitus	Chudyk and Petrella ⁸⁵	1	0	1	1	0	1	0	0	1	0	1	6
	Umpierre et al ⁹⁰	1	1	1	1	0	1	1	1	1	1	1	10
	Irvine and Taylor ⁸⁶	1	1	1	0	0	1	1	1	1	0	0	7
	Thomas et al ⁸⁹	1	1	1	1	1	1	1	1	1	1	1	11
	Kelley and Kelley ⁸⁷	1	1	1	1	0	1	1	1	1	1	0	9
	Snowling and Hopkins ⁸⁸	1	0	1	0	0	1	1	1	1	0	0	6
	Boulé et al ⁸⁴	1	0	1	1	0	1	1	0	1	0	0	6
	HIV	O'Brien et al ⁹¹	1	1	1	1	1	1	1	1	1	0	1
Depression	Krogh et al ⁹³	1	1	1	1	0	1	1	1	1	1	1	10
	Herring et al ⁹⁴	1	0	1	1	0	0	1	1	1	1	1	8
	Mead et al ⁹⁶	1	1	1	1	1	1	1	1	1	1	1	11
	Rethorst et al ⁹⁵	1	1	1	1	0	1	1	0	1	0	1	8
	Lawlor and Hopker ⁹²	1	1	1	1	0	1	1	1	1	0	1	9
Tallies for 58 reports	58	38	54	34	15	49	48	41	42	26	29	434	
Percentage of total (58 reports)	100	66	93	59	26	84	83	71	72	45	50		

Table 3 Characteristics of participants and interventions

Author	RCTs	n (% M or F)	Age (years)	Characteristics of exercise intervention
AECOPD				
Puhan et al ³⁹	9	427 (64% M)	Range 62–70	Mo: AT and RT; Fr: Twice daily – 3×/week; T: NR except one study stated 2 hours/session; D: 10 days–6 months
COPD				
Lacasse et al ⁴²	31	1322	NR	Mo: AT and RT, U/E, L/E, and/or respiratory muscle training; Fr and I: NR; D: 4–52 weeks
O'Shea et al ⁴³	9 of 18	296 of 679 (70% M)	Range 48.5–72	Mo: RT using free weights, machine, Theraband; Fr: 2×/week–daily; I: variable; T: 5–12 reps, 2–4 sets; D: 6–12 weeks
Salman et al ⁴⁴	20	999	59–73	Mo: AT, RT; U/E, L/E, and/or respiratory muscle training; Fr: ≥3 ×/week; D: 6 weeks–12 months; other details NR
Chavannes et al ⁴⁰	4 of 5	210 (~55% M)	49–63	Mo: AT + RT (four studies), AT (one study); Fr: 2–7×/week; D: 8 weeks–18 months; other details NR
Vieira et al ⁴⁵	8 of 12	370 of 728	Range 38–78	Mo: Home-based AT and RT; Fr: 2×/week – twice daily; I: 90% of velocity of 6 MWD, ≥70% of maximal speed of SWT, cycle ergometer: 30 W, cycling: 70% of work rate; T: 30–60 minutes; D: 4–52 weeks
Janaudis-Ferreira et al ⁴¹	5	157	NR	Mo: Arm AT and RT; Fr: 3×/week – 2×/day; I: NR; T: 4–10 reps 1–3 sets; D: 6–8 weeks
Older adults				
Liu and Latham ⁵⁰	83 of 121	3059 of 6700	>60	Mo: RT in gym or against Theraband; Fr: 2–3×/week, except one was daily; I: ranged from low to high intensity; D: most 8–12 weeks but ranged from 2–104 weeks
Howe et al ⁴⁹	34	2883 (<50% M)	60–75 years	Mo: RT, gait, balance, co-ordination, and functional tasks, tai chi, qi gong, dance, yoga; other details NR
Gillespie et al ⁴⁸	14 of 111	55303 (<50% M)	>60	Mo: AT, RT, gait, balance and functional training, flexibility training, tai chi, and square stepping; general physical activity (walking groups); other details NR
Weening-Dijksterhuis et al ⁵²	27	6459	>70	Mo: RT (strength, resistance), ROM, balance, functional, gait, tai chi, flexibility; other details NR
Forster et al ⁴⁷	37 of 49	3611 (33% M)	Mean 82	Mo: RT, AT (walking) and general daily living skills eg, eating, dressing, and climbing stairs, flexibility, balance; Fr: mean of 3.5×/week T: ≤30 minutes/week; D: 4 weeks–2 years
Chin et al ⁴⁶	20	2515 (majority F)	77–88	Mo: AT, RT, flexibility, balance, tai chi, and/or multi-component training; Fr: usually 3×/week; D: range 10–28 weeks
Rydwick et al ⁵¹	16	1269	>70	Mo: RT, gait, and ROM training; Fr: usually 2–3×/week T: variable; D: 9 weeks–2 years
Heart failure				
Davies et al ⁵⁵	19	3647 (majority M)	51–72	Mo: AT or AT + RT; Fr: 2–7×/week; I: 40% max HR or 85% VO ₂ max; T: 15–120 minutes; D: 24 weeks–3 years
Hwang et al ⁵⁴	4 of 8	103 (60% M)	62–77	Mo: RT for U/E and L/E; Fr: 2–3×/week; I: 60%–80% 1RM; T: 12–60 minutes; D: 8–22 weeks
Hwang and Marwick ⁵⁷	19	1069 (85% M)	59.05 (95% CI 55–63)	Mo: AT or AT + RT: cycle ergometer, walking, calisthenics, ball games, strength training; Fr: NR; I: AT: –10% of AT, 60%–80% HRmax, 70% VO ₂ max RT: 80% 1RM, 70% HRmax; T: 40–400 minutes/week; D: 8–52 weeks

(Continued)

Table 3 (Continued)

Author	RCTs	n (% M or F)	Age (years)	Characteristics of exercise intervention
Chien et al ⁵³	10	648 (79% M)	52–81	Mo: Home based AT (walking program, and/or cycle ergometer) and RT (added in 3/10 studies); Fr: 2–5×/week; I: 40%–70% HRmax, or 70% HR at VO ₂ max; T: 20–60 minutes; D: 6–52 weeks. All home programs
Haykowsky et al ⁵⁶	9 of 14	538 of 812 (83% M)	52–61	Mo: AT: cycle ergometer, rowing, swimming, walking, arm ergometer, treadmill, interval training; Fr: 2–7 days/week; I: 50%–80% VO ₂ peak, 60%–85% HRpeak, or 50%–70% max work load; T: 20–60 minutes; D: 2–14 months
van Tol et al ⁵⁸	35	1486 (76% M)	Mean 60.6 (SD 7.5)	Mo: AT + RT; Fr: range 1–7×/week, mean 3.7×/week; I: 50%–80% VO ₂ peak, 60%–80% HRmax, 60%–80% HRR; T: 15–96 minutes, 50 minutes (mean); D: 3–26 weeks, 13.0 weeks (mean)
Spruit et al ⁶¹	4 of 10	114 (72% M)	Mean 57–77	Mo: RT alone Fr: 2–3×/week; I: 40%–80% 1 RM; T: 15–60 reps in 1–3 sets; D: 8–20 weeks; progression described in some reports
Cahalin et al ⁶⁰	11 of 22	387 of 633 (70% M)	30–80	Mo: RT: variety of strength exercises either alone or with short or long bursts of AT; Fr: 2–5×/week; I: RT: 20%–80% 1RM; AT: up to 80% VO ₂ peak, or 70% HRpeak, or 50% peak workload; T: 5–60 minutes; D: 4–26 weeks
Benton ⁵⁹	4 of 16	115 of 379 (80% M)	Mean 30–76	Mo: RT: chair stands, heel lifts, weights, pulleys, hydraulic fitness; Fr: 2–3×/week; I: 60% 1 RM; AT: cycling, arm ergometer, stair climbing, walking; T: 2–60 minutes; D: 2–5 month study duration; reps and progression: variable
Ischemic heart disease				
Haykowsky et al ⁶⁵	12	647	55	Mo: AT: Cycle, walk, jogging, calisthenics; Fr: 3–7×/week; I: 60%–80% VO ₂ max or peak HR; T: 30–180 minutes; D: 1–6 months
Valkeinen et al ⁶⁸	18	922 (majority M)	59.9 ± 4.9	Mo: AT: walking, jogging, cycling, and arm cranking; Fr: 3.1 ± 0.4×/week; I: 70%–80% HRmax, HRR, HR of anaerobic threshold or 25%–70% VO ₂ max; T: 20–60 minutes; D: 14.2 ± 13.5 weeks Mo: RT: Fr: 3.5 ± 0.7×/week; I: 50%–80% 1 RM or 40%–60% MVC; T: 20–60 minutes; D: 22.0 ± 11.1 weeks
Cortes et al ⁶⁴	11 of 14	3148 (≥70% M)	55–65	Mo: Early mobilization: sitting on bed/chair, walking, moving legs, climbing stairs, any movement out of bed, dangling legs, progressive activity while in hospital; settings descriptions: CCU, hospital wards, in-hospital
Jolliffe et al ⁶⁶	32	8440 (majority M)	55	Mo: AT: walking, running, cycling, skipping, swimming, stairs, and rowing; Fr: 1–5×/week; I: 70%–85% HRmax or predicted HRmax, other 75% max work capacity; T: 20–60 minutes; D: 4 weeks to 30 months Mo: RT: strengthening exercises for U/E and L/E; Fr: 3×/week; I: Target HR 85% HRmax; T: 60 minutes; D: 12 weeks
Clark et al ⁶²	41 of 63	8460 of 21295 (majority M)	Mean 49–71	AT, RT: no details on intervention
Cornish et al ⁶³	2 of 7	120 of 213	57 ± 14–71.5 ± 7.8	Mo: AT: interval training: aerobic dance movements, upper/lower body exercises, cycle ergometer, or treadmill walking/running; Fr: 2–3×/week; I: 3 intervals of 5–10 minutes at RPE 15–18 in one study and 3 minutes at 60%–70% HRmax + 4 minutes at 90%–95% HRmax in another; T: 50–60 minutes; D: 16–26 weeks

(Continued)

Table 3 (Continued)

Author	RCTs	n (% M or F)	Age (years)	Characteristics of exercise intervention
Oliveira et al ⁶⁷	4 of 11	126	most <60	Mo: RT: free weights in one study, NR in others; I: 40%–60% MVC or 50%–80% 1 RM; D: 10 weeks to 6 months; Other details NR
PVD				
Watson et al ⁶⁹	16 of 22	783 of 1200 (>50% M)	45–89	Mo: AT, RT: polestriding, cycling, and U/E and L/E exercises. Fr: 2–7×/week; T: 30–120 minutes; D: 3–12 months
Wind and Koelemay ⁷⁰	10 of 15	625 of 761 (>50% M)	60–76	Mo: AT: crank exercise, walking, others not detailed. Fr: 2–3×/week; T: 30–60 minutes; D: 12–26 week except one study was 104 weeks
Hypertension				
Dickinson et al ⁷³	21 of 105	1518 of 6805 (~57% M)	52 (30–67)	Mo: AT: brisk walking, jogging, cycling; Fr: 3–5×/week; T: 30–60 minutes; D: 8–52 week (median 12). 2 trials received RT, but details NR; 1 trial offered advice to participants
Cornelissen and Fagard ⁷²	28 of 72	492 in exercise group	52.7 ± 11.8	Mo: AT: walking, jogging, running, cycling; Fr: 2–7×/week (median 3); I: 30%–87% HRR (median 65); T: 25–60 minutes (median 40); D: 4–52 weeks (median 12)
Whelton et al ⁷⁴	15 of 54	872 (majority M)	Mean 40–69 Range 18–86	Mo: AT: biking, walking, jogging; Fr: 1–7×/week; I: 40%–70% VO ₂ max, 60%–85% HRmax, 40%–70% Wmax; T: 20–60 minutes; D: 3–26 weeks
Kelley et al ⁷¹	47	2543 >50% M	48	Mo: AT: walking, jogging, cycling, aerobic dance, and swimming; Fr: 1–5×/week; I: 45%–86% VO ₂ max; T: 15–60 minutes; D: 360–9360 minutes
Obesity				
Shaw et al ⁷⁶	4 of 41	440 of 3476 (majority M)	30–64	Mo: AT: walking/jogging, circuit training; Fr: 2–3×/week; I: 60%–80% HRmax; T: 30–60 minutes; D: 26–52 weeks
Witham and Avenell ⁷⁵	2 of 9	173 (100% F)	60	Mo: supervised AT, no details; Fr: 3×/week; I: aiming for 70% VO ₂ max; T: NR; D: 3 months; Transition to home: exercise 4×/week plus weekly supervised exercise
OA				
Devos-Comby et al ⁷⁹	16	2154	Mean 65.8, range 29–89	Mo: AT + RT: knee muscles strength training, low/medium intensity exercise, and light physical activity (walking, aerobic exercise, balance or flexibility exercises); Fr: 2–5×/week (sometimes 2×/day); I: AT: 50%–85% HRR, RT: 6 set × 5 max contraction (others NR); T: 20 minutes – 1.5 hour; D: 4–12 weeks (different follow-up periods)
Lange et al ⁸⁰	18	2723	Range 55–74	Mo: RT: dynamic or isotonic training mainly targeting the quadriceps using resistance machines, free weights, or Theraband; Fr: 2–7×/week; I: light to maximal; T: 10–60 minutes, 5–12 reps, 1–10 sets (most 3 sets); D: 1–30 months
Ottawa Panel ⁷⁷	26	2486	>18	Mo: AT: walking or cycle ergometer; RT: strengthening (eg, isometric, isotonic, isokinetic, eccentric, concentric, aerobic), general physical activity, combination of exercises; Fr: 1×/week–10×/day (depends on phase); I: AT: 50%–70% HRR when described, RT: variable. T: 5 minutes–1.5 hours; D: 4 weeks–18 months
Brosseau et al ⁷⁸	9 of 12	1363	57–69.4	Mo: AT: walking, stationary bike; Fr: 1–4 ×/week; I: 50%–85% HRR or 60%–80% HRmax. T: 30–90 minutes when reported; D: 5–12 weeks. Some changed to home-based program up to 15 months. Some studies included strengthening exercises

(Continued)

Table 3 (Continued)

Author	RCTs	n (% M or F)	Age (years)	Characteristics of exercise intervention
Pelland et al ⁸¹	17 (plus 4 CCTs)	2325	Range 55.0–74.6	Mo: ROM exercises, low intensity walking on treadmill, RT: quadriceps, hamstrings, and hip abduction strengthening, stationary bike; Fr: most 2–3×/week, range: 1×/week–2×/day; I: variable; T: 15–40 minutes, 3–9 exercises, 6–20 reps, 1–4 sets; D: 4 week–15 months
Osteoporosis				
Li et al ⁸³	5 groups in 4 papers	256 (100% F)	NR	Mo: RT or combined stretch/strength/balance programs: strengthening of extremities and trunk (1 study), “agility” training (1 study), combined exercise (stretching, strengthening, balance, posture) (2 studies), trunk flexor/extensor strengthening (1 study); Fr: 3 studies 2 days/week, 1 study 7 days/week; I: NR; T: 40–60 minutes; D: 10–25 weeks
De Kam et al ⁸²	28	1707, some reports used the same subjects	Mean 57–82	Mo: fast walking; aerobic exercise; weight-bearing aerobic exercise; strengthening exercises; balance exercises; posture and gait exercises; trunk extensor exercises; heel drops with impact; heel drops with no impact; whole body vibration; jumping; agility training including ball games, relay races and obstacle courses; tai chi; home-based walking, strengthening and stretching; Fr: 3–7×/week; I: not described – only one study described progression by increasing step count by 30%; T: 4–90 minutes; D: 10–104 weeks
Diabetes				
Chudyk and Petrella ⁸⁵	30 of 34	NR	NR	Mo: AT; Fr: most 3×/week but range of 1–7×/week; I: 50%–85% VO ₂ max or 35%–85% HRmax; T: 40–75 minutes; D: 2–24 months. RT: variable
Umpierre et al ⁹⁰	23 of 47	1513 of 8538	Range of means 52–69	Mo: AT, RT; Fr: 2–5×/week T: AT: 30–150 minutes/week and RT: 9–27 sets; D: 12–52 weeks
Irvine and Taylor ⁸⁶	7 of 9	162 of 256	47–68	Mo: RT: free weights or weight machines; Fr: 2–3×/week; I: 55%–85% 1RM or to moderate on Borg; T: 8–15 reps, 1–3 sets, 5–10 exercises; D: 8–26 weeks
Thomas et al ⁸⁹	14	377	45–65	Mo: qi gong, RT, AT: cycle ergometer, walking cycling, skiing, swimming; Fr: 3–7×/week; I: AT: 50%–85% VO ₂ peak, 65%–75% HRR or 85% HRmax; T: 30–120 minutes; if PRT, 2–3 sets of 10–12 reps; D: 8 weeks–1 year
Kelley and Kelley ⁸⁷	7	Both	40–75	Mo: AT: cycle ergometer, walking, jogging, cycling, swimming, skiing; Fr: 3–7×/week I: 60%–75% VO ₂ max; T: 30–75 minutes; D: 10–26 weeks
Snowling and Hopkins ⁸⁸	27	1003	55 ± 7	Mo: AT; Fr: 3–7×/week; I: 50%–85% VO ₂ max, HR 110–140 bpm, 40%–80% HRR; T: 30–120 minutes; D: 6–104 weeks. Mo: RT; Fr: 3–5×/week; I: 50%–80% of 1 RM; T: 10–20 reps, 2–3 sets, 5–10 ex; D: 5–16 weeks
Boulé et al ⁸⁴	27	266	55.7	Mo: AT: continuous aerobic; walking, cycling, skiing jogging, rowing, Theraband; Fr: 3–6×/week; 60%–75%; I: VO ₂ max; T: 40–60 minutes; D: 8–52 weeks
HIV				
O'Brien et al ⁹¹	7 of 14	306 of 454 (~70% M)	18–58	Mo: AT: interval or continuous aerobic, walking, jogging, stair stepping, ski machine, stationary bike, cross country machine. Fr: 3×/week I: AT: usually 50%–85% VO ₂ max and 60%–80% HRmax or RT: 60%–80% 1 RM; T: 20–60 minutes, D: 5–24 weeks

(Continued)

Table 3 (Continued)

Author	RCTs	n (% M or F)	Age (years)	Characteristics of exercise intervention
Depression/anxiety				
Krogh et al ⁹³	13	272	17–85	Mo: AT, RT, AT + RT; Fr: 2–5×/week; D: 8–16 week; AT: I: 70%–80% HRmax, 50%–70% aerobic capacity; T: 30–60 minutes. RT: I: 80% RM; T: 20 minutes or 8 reps × 3 sets
Herring et al ⁹⁴	40	NR (59% F)	50 ± 10	Mo: AT, RT, AT+RT; Fr: 3 ± 1×/wk; I: variable; T: 42 ± 22; D: 16 ± 10 wk
Mead et al ⁹⁶	23 of 25	640	≥ 18	Mo: AT: running, treadmill walking or walking, stationary cycling; RT; Mixed: A + RT, qi gong exercises, individually tailored, tai chi; D: 10 days – 16 weeks
Rethorst et al ⁹⁵	58	2982	15–94	Mo: AT; Fr: 3–5×/week; I: moderate to high T: 20–60 minutes; Mo: RT; F: 2–3 × /week T: 20–60 minutes; Mo: A + RT; T: 20–90 minutes; D: acute – 52 week
Lawlor and Hopker ⁹²	11 of 14	479 (~34% M)	All ages	Mo: AT: running, walking; Fr: 2–5×/week; T: 20–60 minutes; D: 4–12 week

Notes: In RCT columns, number of RCTs from total number of studies. In number of subject's (n) columns, number of subjects that were analyzed and total number of participants.

Abbreviations: AECOPD, acute exacerbation of COPD; AT, aerobic training; D, duration of training program; Fr, frequency; HRR, heart rate reserve; I, intensity; L/E: Lower extremity; M, male; F, female; Mo, modality; mod, moderate; NR, not reported; RT, resistance training; T, session time; U/E, upper extremity; ROM, range of motion; SWT, shuttle walking test; PRT, progressive resistance training.

AT and RT of the extremities improved maximal exercise capacity, walk distance performance, and quality of life measures in outpatient COPD compared to a control group as described by a high quality SR with an AMSTAR score of 10.⁴² Whether people with mild-to-moderate COPD with AECOPD benefit from exercise training is equivocal, as summarized by two SRs with AMSTAR scores of 5 and 8.^{40,44} Exercise training that focused on RT improved leg strength and cycling endurance as described by one review with an AMSTAR of 8.⁴³ Unsupported and supported arm exercise showed improvement in half of the studies evaluated by one SR.⁴¹ Home exercise demonstrated improvement in exercise capacity in all studies that assessed this attribute and half of the studies that assessed quality of life.⁴⁵ Dyspnea was significantly improved by aerobic and resistance trainings in two reports.^{42,44}

Walking and cycling were the most common AT whereas free weights and TherabandTM were the most common resistance used during RT. Frequency of training ranged from twice weekly to twice daily. The intensity of aerobic training was either not described in the SRs or, in one report, was quantified as a percentage of walk test distance.⁴⁵ RT intensity ranged from one-third of a (repetition maximum) RM to near maximal intensity for the number of repetitions. The time for each session varied between 30 and 120 minutes, or was defined in terms of repetitions and sets for RT.^{41,43} Durations of studies ranged between four weeks and 18 months. There was an obvious focus on AT and RT in the SRs, and no

reports described the outcomes from balance or functional training in people with COPD.

Older adults

Overall, exercise training results in improved physical and functional performance for older adults, as demonstrated by seven SRs,^{46–52} although initial health status influenced both the ability to participate in certain programs as well as the outcomes of the training. Most SRs and many RCTs included a mix of RT, BT, and functional training rather than focusing on a single type of training. Thus, evidence for the most part is provided from multifaceted training rather than a singular approach. Many other aspects of the training varied widely, with a training frequency most often of two to three times a week, total duration that ranged from 2 to 104 weeks, and a variable intensity level (Table 3). SRs, which had AMSTAR scores ranging from 5 to 11, showed that mixed training improved balance^{47,49,52} and strength,^{47,51,52} reduced falls,⁴⁸ and improved functional measures such as the 6-minute walk distance (6MWD).^{46,49,51,52} An SR that had a singular focus on RT with an AMSTAR of 11 showed widespread improvements in lower extremity strength, aerobic capacity, and several physical performance tests (Table 4).⁵⁰ In addition, this SR provided evidence that RT reduced the relative risk of death and pain.⁵⁰

Heart failure

Six meta-analyses^{53–58} investigated the benefits of AT and/or RT in patients with chronic heart failure. Most of these papers

Table 4 Generic and disease-specific outcomes from exercise interventions

Author	Condition and severity	Type of training:	Generic fitness, quality of life and functional outcomes # RCTs/n/difference [95% confidence intervals]	Disease specific fitness, control and prevention outcomes # trials/n/difference [95% confidence intervals]
Puhan et al ³⁹	COPD after AECOPD	AT, RT	6MWD: 6/NR/WMD: 77.7 m [12.2, 143.2]; Shuttle walk test: 3/NR/WMD: 64.4 m [41.3, 87.4]; QoL: SGRQ: 3/NR/WMD: 9.88 [-14.40, -5.37] Maximal exercise capacity on cycle ergometer: 13/51/WMD: 8.4 watts [3.45, 13.41]; 6MWD: 16/669/WMD: 48.5 m [31.6, 65.3]; QoL: Fatigue of CRQ: 11/618/ WMD: 0.92 [0.71, 1.13] Leg press strength: 4/77/SES: 0.96 [0.26, 1.66]; Knee extensor strength: 3/125/SES: 0.52 [0.30, 0.74]; Cycling endurance: 2/52/SES: 0.87 [0.29, 1.44]. Walking distance: 20/979/SES: 0.71 [0.43, 0.99] Exercise tolerance: Limited evidence of improvement. SES NR	Dyspnea: 5/NR/0.97 [0.35, 1.58]; Admission to hospital: 5/250/OR: 0.22 [0.08, 0.58]; Mortality: 3/110/OR: 0.28 [0.10, 0.84] QoL: Change in dyspnea of CRQ: 11/618/WMD: 1.06 [0.85, 1.26]
Lacasse et al ⁴²	COPD	AT, RT		
O' Shea et al ⁴³	Mild to severe COPD	RT		
Saiman et al ⁴⁴	Mild to severe COPD	AT, RT		
Chavannes et al ⁴⁰	Mild to mod. COPD	AT, AT + RT,		
Vieira et al ⁴⁵	COPD	Home based AT, RT		Shortness of breath: 12/723/SES: 0.62 [0.26, 0.91]
Janaudis-Ferreira et al ⁴¹	Mod. to severe COPD	Arm AT, RT		
Liu and Latham ⁵⁰	Elderly	RT	Lower limb strength: 73/3059/SES 0.84 [0.67, 1.00]; VO ₂ max: 18/710/WMD 1.50 mL/kg/min [0.49, 2.51]; 6MWD: 11/325/WMD 52.37 m [17.38, 87.37]; Gait speed: 24/1179/WMD 0.08 m/s [0.04, 0.12]; Timed up-and-go: 12/691/WMD -0.69 s [-1.11, -0.27]; Time to stand from a chair: 11/384/SES -0.94 [-1.49, -0.38]; Stair climbing: 8/268/-1.44 s [-2.51, -0.37]; Vitality: (SF-36) 10/611/WMD 1.33 [-0.89, 3.55]; Main function: 33/2172/SES 0.14 [0.05, 0.22] Single leg stance time, eyes open: 4/164/MD 0.33 s [0.02, 0.64]; Berg Balance Scale 3/126/MD 2.72 [0.94, 4.50]	Death: 13/1125/RR 0.89 [0.52, 1.54]; Pain: 6/503/SES -0.30 [-0.48, -0.13]
Howe et al ⁴⁹	Improving balance	Balance, gait, functional task		
Gillespie et al ⁴⁶	Falls prevention	Balance, gait, functional		Rate of falls: 3/461/RR: 0.73 [0.54, 0.98] 0.036; Number of fallers: 17/2492/RR: 0.83 [0.72, 0.97] 0.018
Weening-Dijksterhuis et al ⁵²	Institutionalized frail elderly	AT, RT, balance and functional training	Strength: ↑ in 8 of 9 studies; 6MWD: ↑ in 3 of 3 studies; Balance: ↑ in 10 of 10 studies; Psychological function/perceived health: some effect; Function: ↑ in 4 of 4 on depression and activity measures	

(Continued)

Table 4 (Continued)

Author	Condition and severity	Type of training:	Generic fitness, quality of life and functional outcomes # RCTs/n/difference [95% confidence intervals]	Disease specific fitness, control and prevention outcomes # trials/n/difference [95% confidence intervals]
Forster et al ⁴⁷	Elderly in long term care	AT, RT and balance	Mobility (variety of tests): ↑ in 24 of 35 trials; Strength: ↑ in 18; Balance: ↑ in 12 of 16 studies Physical Performance Test: ↑ in 3 of 4 studies; 6MWD: ↑ in 9 of 17 studies	
Chin et al ⁴⁶	Frail, Elderly	AT, RT and balance	Strength: ↑ in 6 of 9 studies; Mobility: ↑ in 8 of 12 studies;	
Rydwik et al ⁵¹	Institutionalized elderly, multiple diagnoses	AT, RT, balance, mobility, gait, ADL	Range of motion: ↑ in 2 of 3 studies; Gait: ↑ in 4 of 8 studies; Activities of daily living: ↑ in 3 of 6 studies	
Davies et al ⁵⁵	HF, severity not an inclusion criterion	AT, RT		Hospital admissions related to heart failure: 7/569RR: 0.72 [0.52, -0.99]; QoL using Minnesota Living with Heart Failure Questionnaire: 6/700WMD -10.3 [-15.9, -4.8]; QoL using all scales: 9/779/SMD: -0.57 [0-0.83, -0.31]
Hwang et al ⁵⁴	HF, diagnosis based on clinical signs or LVEF < 40%	RT	6MWD: 2/40/52 m [19, 85]	
Hwang and Marwick ⁵⁷	HF	AT (15) or AT + RT (4)	VO ₂ max: 16/733/2.86 mL/kg/min [1.43, 4.29]; Exercise duration: 7/241/2.00 min [1.43, 2.57]; 6MWD: 6/628/30.4 m [6.1, 54.7]	
Chien et al ⁵³	HF, diagnosis based on clinical signs or LVEF < 40%	Mostly AT, home-based. RT added in 3/10 studies	VO ₂ max: 7/355/MD 2.71 mL/kg/min [0.67, 7.74]; 6MWD: 5/320/MD 41.09 m [19.12, 63.06]	Hospitalization due to cardiac events: 2/143/OR 0.75 [0.19, 2.92]
Haykowsky et al ⁵⁶	HF, severity not a criterion, clinically stable	AT	VO ₂ max: 9/538/WMD 2.98 mL/kg/min [2.47, 3.49]	Ejection fraction: 9/538/WMD 2.59% [1.44, 3.74]; End-diastolic volume: 5/371/WMD -11.49 mL [-19.95, -3.02]; End-systolic volume: 5/371/WMD -12.87 mL [-17.80, -7.93]
van Tol et al ⁵⁸	HF, severity not a criterion for inclusion	AT, RT	VO ₂ max: 31/1240/MD 2.06 mL/kg/min; Watts on maximal test: 19/715/MD 14.3 W; Anaerobic threshold: 13/511/MD 1.91 mL/kg/min; 6MWD: 15/599/MD 46.2 m; HR during maximal exercise: 18/683/MD 3.5 bpm; SBP during maximal exercise: 10/382/MD 5.4 mmHg; QoL: 9/463/MD -9.7 points	End-diastolic volume at rest: 9/527/WMD -3.13 mL; Cardiac output during maximal exercise: 3/104/WMD 2.51 L/min
Spruit et al ⁶¹	HF, severity not a criterion for inclusion	RT	Mean peak isotonic strength of upper and lower body: 1/16/37% improvement; Muscle endurance: 1/16/299% improvement	

Cahalin et al ⁶⁰	HF, severity not a criterion	RT, with short or long bursts of AT	Muscle strength, muscle endurance, daily activity, forearm blood flow, performance of heel lift, and QoL increased and resting HR decreased, but no synthesis of data from more than one RCT was provided	Left ventricular ejection fraction, left ventricular fractional shortening, and insulin-stimulated glucose uptake improved, but no synthesis of data from more than one RCT was provided
Benton ⁵⁹	HF, severity not a criterion	AT, RT	Muscle strength, muscle endurance, QoL, heart rate during exercise, and forearm blood flow improved, but no synthesis of data from more than one RCT was provided	Meta-regression analysis shows that exercise training had beneficial effects on LV remodeling in clinically stable post-MI patients with greatest benefits occurring when training starts earlier following MI (from one week and lasts longer than 3 months) Ejection fraction: $Q = 25.48$, $df = 2$, $P < 0.01$; End systolic volume: $Q = 23.89$, $df = 2$, $P < 0.005$; End diastolic volume: $Q = 27.42$, $df = 2$, $P < 0.01$
Haykowsky et al ⁶⁵	Post-MI	AT		
Valkeinen et al ⁶⁸	Ischemic heart disease (MI, angina, CABG, PTCA, angioplasty, percutaneous intervention)	AT (majority), RT	VO_2 max for aerobic training: 15/807/SMD 0.67 mL/kg/min [0.39, 0.94]; Longer exercise training period (>6 months) starting soon after a cardiac event (<3 months) had a significant effect on VO_2 max in patients with CHD: 7/406/SMD 0.94 mL/kg/min [0.38, 1.50] and 1/647/SMD 0.77 mL/kg/min [0.44, 1.10, $P < 0.001$] respectively	Trend towards decreased total mortality and non-fatal re-infarction, but n.s Comprehensive cardiac rehabilitation: Total cardiac death: 22/2903/OR 0.75 [0.59, 0.97]; Total cholesterol: 9/1198, -0.65 mmol/L [-0.75, -0.55]; LDL cholesterol: 6/728, -0.61 mmol/L [-0.73, -0.50]; Triglycerides: Small but significant reduction (no numbers) Exercise only: Total cardiac death: 8/2312/OR 0.70 [0.51, 0.94]; Total mortality: 12/2582/OR 0.74 [0.56, 0.98] Program with exercise: Recurrent MI: 12/3997/RR 0.62 [0.44, 0.87] Exercise only: Mortality: 11/2285/RR 0.72 [0.54, 0.95]
Cortes et al ⁶⁴	Acute myocardial infarction	In hospital early mobilization		
Jolliffe et al ⁶⁶	Coronary heart disease	AT (majority), RT		
Clark et al ⁶²	Ischemic heart disease	AT, RT (no details)		
Cornish et al ⁶³	Ischemic CAD (narrative review)	AT (interval training)	Exercise capacity: 2 studies (of 2) showed ↑ in either 6 MWD, cycle test time, VO_2 max, time to fatigue and HRrest, while both showed increase in workload and HRrest; 2 of 2 studies showed ↑ in 6MWD; Muscle strength: 2 studies (of 2) showed ↑ in muscle strength	
Oliveira et al ⁶⁷	Post-MI, CABG (narrative review)	RT		

(Continued)

Table 4 (Continued)

Author	Condition and severity	Type of training	Generic fitness, quality of life and functional outcomes # RCTs/n/difference [95% confidence intervals]	Disease specific fitness, control and prevention outcomes # trials/n/difference [95% confidence intervals]
Watson et al ⁶⁹	PVD	AT, RT	Maximal walking time: 7/255/ MD: 5.1 [4.5, 5.7]; Maximal walking distance: 6/391, MD: 113.20 M [95.0, 131.4]	Pain-free walking time: 3/150, MD: 2.9 min [2.5, 3.3]; Pain-free walking distance: 6/322, MD: 82.2 M [71.7, 92.7]
Wind and Koelemay ⁷⁰	PVD	AT	Walking distance: 9/499, WMD: 155.8 M [80.8, 230.7]	Pain free walking distance: 8/409, WMD: 81.3 M [35.5, 127.1]
Dickinson et al ⁷³	Hypertension	AT	SBP: 21/1346/MD: -6.1 mmHg [-10.1, -2.1; I ² = 87%]; DBP: 21/1346/MD: -3.0 mmHg [-4.9, -1.1; I ² = 74%]	
Cornelissen and Fagard ⁷²	Hypertension	AT	VO ₂ max: 17/279/WMD 4.4 mL/kg/min [3.7, 5.1]; HR: 23/340/WMD -4.5 bpm [-6.5; -2.6]; SBP: 30/492/WMD -6.9 mmHg [-9.1; -4.6]; DBP: 30/492/WMD -4.9 mmHg [-6.5; -3.3].	
Whelton et al ⁷⁴	Hypertension	AT	SBP: 15/NR/ES -4.94 mmHg [-7.17, -2.70]; DBP: 13/NR/ES -3.73 mmHg [-5.69, -1.77]	
Kelley et al ⁷¹	Hypertension	AT	SBP: -6 mmHg [-8, -3] (number of trials/subjects NR); DBP: -5 mmHg [-7, -3] (number of trials/subjects NR)	
Shaw et al ⁷⁶	Obesity	AT	DBP: 2/259/WMD -2.09 mmHg [-3.68, -0.51]	Triglycerides: 3/348/WMD -0.18 mmol/l [-0.31, -0.05]; Fasting glucose: 2/273/WMD -0.17 mmol/l [-0.30, -0.05]; HDL: 3/348/WMD 0.06 mmol/l [0.03, 0.09]
Witham and Avenell ⁷⁵	Obese postmenopausal women	AT, RT	VO ₂ max: increase by 11.7% in the intervention group and 0.7% in the control group at 12 months (P < 0.001)	
Devos-Comby et al ⁷⁹	OA	AT, RT, and balance	Direct measures of impairment (walking distance test, timed chair rise, time getting out of a car, balance tests, or gait): 11/1740/ SES 0.15 [0.08, 0.23]	Combined physical outcomes (Scales of physical disability, discomfort, pain, function, mobility ie, AIMS); 12/808/SES: 0.29 [0.23, 0.36].
Lange et al ⁸⁰	Knee OA	RT	Strength: ↑ in 9 of 14 studies; Maximal gait speed: ↑ in 4 of 4 studies; Maximal stair climb/descent: ↑ in 3 of 5 studies	Pain: ↑ in 10 of 18 studies; Physical disability: ↑ in 11 of 14 studies; Physical self efficacy: ↑ in 2 of 2 studies
Ottawa Panel ⁷⁷	OA	AT, RT	Strength, aerobic capacity, and functional status: different levels of evidence support various types of strengthening, mobility and flexibility exercises based on RCTs but no synthesis of data from more than one RCT was provided	Pain: different levels of evidence from RCTs show that different types of exercise decrease pain. No synthesis of data from more than one RCT was provided
Brousseau et al ⁷⁸	OA	AT	Aerobic capacity, timed walk distance, walk velocity: ↑ in RCTs but no synthesis of data from more than one RCT was provided	
Pelland et al ⁸¹	OA – most knee or hip	Mainly RT	Strength, function and QoL: improves, but no synthesis of data from more than one RCT was provided	Pain: decreases, but no synthesis of data from more than one RCT was provided
Li et al ⁸³	Osteoporosis or osteopenia; severity not an inclusion criteria	RT or combined stretch/strength/balance programs	QoL: All domains of SF36 were significantly improved for all 4 studies. Scores out of 100. Physical function: 5/288/WMD 2.77 [2.27, 3.37]; Pain: 5/288/WMD 4.95 [3.52, 8.70];	

De Kam et al ⁸²	Osteoporosis or osteopenia	AT, RT, Balance, Gait	<p>Improvements in: spine BMD, hip BMD, femur BMD, fall-related fractures; radius BMD, calcaneus BMD, fall risk reduction; tibia BMD, falls incidence; vertebral height</p> <p>HbA_{1c} AT: WMD: -0.62% [-0.98, -0.27]; AT + RT: WMD: -0.67% [-0.93, -0.40]; Triglycerides AT: WMD: -0.29 mmol/L [-0.48, -0.11]; AT + RT: WMD: -0.30 mmol/L [-0.57, -0.02].</p> <p>HbA_{1c} AT: 18/848/WMD: -0.73% [-1.06, -0.40]; RT: 4/261/WMD: -0.57% [-1.14, -0.01]; AT + RT: 7/404/WMD: -0.51% [-0.79, -0.23].</p> <p>HbA_{1c}: 7/NR/SES: -0.25 [-0.47, -0.03] HbA_{1c}: 13/361/MD: -0.62% [-0.91, -0.33].</p> <p>Low density lipoprotein: WMD: -6.4 mg/dl [-11.8, -1.1].</p> <p>HbA_{1c} AT: 17/NR/WMD: -0.7% [-1.0, -0.4]; RT: 6/NR/WMD: -0.5% [-1.0, -0.1]; A + RT: 5/NR/WMD: -0.8% [-1.3, -0.2].</p> <p>HbA_{1c}: 8/NR/WMD: -0.71 [-1.1, -0.32] Interval AT: CD4 cell counts: 2/45/WMD: 69.6 cells/mm³ [14.1, 125.1]; AT: Profile of moods: 2/65/WMD: -7.7 [-13.5, -1.9]. Depressive symptoms: 13/272/SES: -0.40 [-0.66, -0.14] Anxiety symptoms: 38/NR/SES: 0.29 [0.23, 0.36]</p> <p>Depression symptoms AT: 17/640/SES: -0.63 [-0.95, -0.30]; RT: 2/69/SES: -1.34 [-2.07, -0.61]; A + RT: 4/198/SES: -1.47 [-2.56, -0.37] Depression scores: 58/2982/SES: -0.80 [0.92, 0.67]. Depressive symptoms: 9/461/SES: -1.1 [-1.5 to -0.6]; Beck depression: 9/461/WMD: -7.3 [-10.0, -4.6]</p>
Chudyk and Petrella ⁸⁵	Type 2 DM	AT 21 RCT AT + RT	<p>Improvements in: TUG, standing up and walking around cones, U/E strength, posturagraphy; figure 8 walking; L/E strength; trunk strength; step test; lateral reach; walking velocity; balance performance</p> <p>SBP: AT: -6.1 mmHg [-10.8, -1.4]; AT + RT: -3.6 mmHg [-6.9, -0.2]</p>
Umpierre et al ⁹⁰	Type 2 DM	AT, RT, AT + RT	<p>Strength: 4/NR/SES: 0.95 [0.58, 1.31] VO₂ max: 3/95/MD: 4.8 mL/kg/min [2.6, 7.1] A + RT: SBP: 5/NR/WMD: -5.6 mmHg [-9.3, -1.8]; DBP: 5/NR/WMD: -5.5 mmHg [-9.9, -1.1].</p>
Irvine and Taylor ⁸⁶	Type 2 DM	RT	<p>VO₂ max: 9/266/SES: 0.53 [0.18, 0.88] VO₂ max: 5/276/WMD: 2.6 mL/kg/min [1.2, 4.1]; Strength: ↑ in 5 of 6 studies</p>
Thomas et al ⁸⁹	Type 2 DM	AT or RT	
Kelley and Kelley ⁸⁷	Type 2 DM	AT	
Snowling and Hopkin ⁸⁸	Type 2 DM	AT, RT, or A + RT	
Boulié et al ⁸⁴	Type 2 DM	AT	
O'Brien et al ⁹¹	HIV – range of severity	AT	
Krogh et al ⁹³	Depression	9 AT; 3 RT; 1 A + RT	
Herring et al ⁹⁴	Anxiety and chronic illness	AT, RT, balance	
Mead et al ⁹⁶	Depression	AT, RT, A + RT	
Rethorst et al ⁹⁵	Depression	AT, RT, AT + RT	
Lawlor and Hopker ⁹²	Depression	AT	

Notes: WMD (weighted mean difference) is a calculation that provides an average mean difference of studies by weighting the means more highly when the n is larger and the variance is smaller. If the WMD is provided, the unit value for the measure is shown. SES (standardized effect size) is usually calculated by determining the difference between the pre-post values for the intervention and control groups and dividing this difference by the respective standard deviation of differences for the intervention group or the average SD of the differences for both groups.

Abbreviations: AT, aerobic training; BMD, bone mineral density; DBP, diastolic blood pressure; HbA_{1c}, glycosylated hemoglobin; MD, mean difference; OR, odds ratio; QoL, quality of life; RR, rate ratio; RT, resistance training; SES, standardized effect size; 6 MWD, six-minute walking distance; SBP, systolic blood pressure; TUG, timed up-and-go; WMD, weighted mean difference.

had AMSTAR scores ranging from 6 to 8, although one⁵⁷ had a score of 3. Based on these papers, it can be concluded that AT and RT significantly improved numerous cardiopulmonary exercise outcomes, including increasing VO_2 max, 6MWD, maximal workload, and anaerobic threshold. It also improved several cardiac system factors, including increasing the heart rate and cardiac output during maximal exercise, improving left ventricular ejection fraction, and the end-diastolic and end-systolic ventricular volume. Two meta-analyses also reported that exercise significantly improved quality of life in these patients.^{55,58}

There were no meta-analyses that investigated the role of AT and/or RT on muscle strength or endurance. Three reviews without meta-analyses investigated the benefits of exercise on a large number of outcomes, including several that are specific to muscle performance.^{59–61} Exercise improved upper and lower extremity strength and muscle endurance, increased oxidative enzyme activity in the quadriceps muscle, and increased forearm blood flow. However, these results must be interpreted with caution as these reports were SRs without meta-analyses, and the AMSTAR scores were relatively low (2 to 6), with few details quantifying the magnitude of the effect.

The AT was relatively consistent across all the studies, in terms of frequency, mode, and intensity. Subjects exercised 2–7 days per week, with most trials within each SR providing the exercise intervention for 3 days per week. Cycle ergometry and treadmill walking were the most commonly used modalities. Most studies prescribed an AT intensity based on a maximal cardiopulmonary exercise test, with exercise intensities ranging from 50% to 80% of VO_2 max. The time per session and the durations of the programs were very variable, ranging from 12 to 100 minutes and 1 to 14 months, respectively. Where described, the resistance training prescription tended to be based on 40% to 80% of one RM.

Ischemic heart disease

Seven SRs investigated the benefits of early mobilization, anaerobic training, and/or RT in ischemic heart disease patients.^{62–68} The AMSTAR scores ranged from 3 to 10, with two reviews having a score of 3,^{63,67} and one a score of 5.⁶⁸ The remaining reviews had AMSTAR scores exceeding 8.

The study populations were predominantly male. There was variation in the specific type of intervention (both AT and RT), and differing endpoints were utilized to evaluate benefit and responses. Five reviews examined the effects of AT,^{62,63,65,66,68} three reported the effects of both AT and

RT,^{62,66,68} one examined the sole effect of early in-hospital mobilization,⁶⁴ and one examined the sole effect of RT.⁶⁷ Some work focused on reporting disease-specific outcomes (ie, recurrent myocardial infarction, cholesterol and triglyceride levels, ejection fraction, and end-systolic and end-diastolic volumes),^{62,64,65,66} while others studied indices of overall activity and fitness (ie, walking distance, maximal aerobic capacity, exercise duration, and muscle strength)^{63,67,68} in these populations with ischemic heart disease. Quality of life and health care utilization were not studied or specifically reported, and significant variation was evident in the duration of follow-up.

Early in-hospital mobilization demonstrated nonsignificant trends towards decreased total mortality and nonfatal re-infarction.⁶⁴ The results suggest that anaerobic and RT reduces the risk of total cardiac death, recurrent myocardial infarction, as well as cholesterol and triglyceride levels. Improvements were also demonstrated in peak oxygen uptake, exercise duration, exercise workload, and 6MWD. The findings suggest that benefits were greater when exercise programming was initiated soon after an ischemic event (as early as 1 week post-myocardial infarction), and when exercise program duration exceeded either 3 or 6 months (rather than <3 months).

Peripheral vascular disease

Exercise training significantly improved the walking distance and pain-free walking distance in patients with peripheral vascular disease (PVD) when compared to standard care as evidenced by two meta-analyses with relatively high AMSTAR scores of 9 and 7.^{69,70} Exercise training was generally supervised. The optimal intensity was not clear, although it was suggested that patients exercised until near maximal pain. The majority of the studies applied an exercise regimen of two to three times per week for 30–60 minutes, with these usually incorporating walking, leg exercises, or treadmill training. Some encouraged additional home exercise.

Hypertension

Exercise training (mainly aerobic exercise) significantly lowered the systolic (SBP) and diastolic blood pressure (DBP) in people with hypertension, as supported by four meta-analyses.^{71–74} Two of the SRs^{73,74} had AMSTAR scores of 8 of 11 while two others had scores of 7 and 4.^{71,72} VO_2 max increased significantly and resting heart rate (HR) decreased after exercise training.⁷² Exercise training also demonstrated significant improvement in cardiovascular risk factors as shown by an increase in high density lipoprotein

cholesterol, and decreases in glucose, insulin levels, and the homeostatic model assessment index (a measure of insulin resistance), despite the inclusion of normotensives in the analysis.⁷² Reductions were greater for SBP in African–American individuals and for DBP in Asian individuals, but only a small number of trials were conducted in people of different ethnic backgrounds.⁷⁴

A variety of study designs were included in the meta-analyses, but the majority of the studies included training programs that involved mainly aerobic exercise (walking, jogging, cycling), usually three to five times per week, for 30 to 60 minutes, at moderate intensity. According to two SRs there is no relationship between blood pressure (BP) response and training characteristics (intensity, frequency), except for a lesser BP reduction associated with a longer total trial duration, probably due to loss of compliance in long trials.^{72,74}

Because aerobic exercise also showed positive effects in normotensives, these data suggest that aerobic exercise is an important strategy not only in treating high blood pressure, but could potentially be used as prophylaxis.⁷⁴

Obesity

Data on the effect of physical activity on fitness outcomes in this population were limited. In post-menopausal obese women, an exercise-based program improved VO_2 max as shown in one RCT reported by one SR.⁷⁵ A Cochrane review with an AMSTAR score of 11 did not report the effect of physical activity on VO_2 max but found a decrease in DBP, reduced triglycerides and glucose, and increased HDL levels.⁷⁶ The majority of trials in the two SRs consisted of AT, usually two to three times per week, at 60%–80% of VO_2 max or HRmax, with different durations utilized.

Osteoarthritis

Results from the five SRs examining the effects of exercise on patients with knee or hip OA consistently show beneficial results for fitness levels and functional performance, though emphasis was primarily on disease-specific outcomes such as joint pain or physical dysfunction.^{77–81} AMSTAR scores were between 7 and 9, and most studies failed to report publication bias or conflicts of interest.

Isotonic RT targeting the quadriceps or hamstrings muscle groups was the most common exercise intervention, though AT and range of motion exercises were also included. Control interventions primarily included patient education or usual care with no additional treatment. Most exercise interventions lasted 3–6 months, though some were

as short as 4 weeks and as long as 24 months. Some studies required daily exercise, while others included only two or three sessions per week. Individual sessions were typically 45–60 minutes in length and complied with usual dosage characteristics for exercise in healthy populations (ie, three sets of ten repetitions for resistance training, and 50% to 80% of maximum heart rate for aerobic interventions).

Pain and physical function were consistently improved following exercise, but no particular type of exercise was found to be superior. Studies examining RT found improvements in strength compared to control interventions,^{77,81} while studies examining the effects of AT found improvements in aerobic capacity, walking speed, and walking distance.^{77–80} All studies found exercise to be a safe and feasible intervention with minimal side effects for patients with OA.

Osteoporosis

Most of the SRs identified in this study investigated the benefits of exercise in the prevention of osteoporosis or osteopenia in healthy, pre- or post-menopausal women. Two SRs investigated the impact of exercise in women diagnosed with osteoporosis or osteopenia, and these had AMSTAR scores of 7⁸² and 6⁸³, indicating moderate quality overall. One of these was an SR without a meta-analysis that evaluated the benefits of AT, RT, BT, and gait on numerous exercise- and disease-related outcomes. It was reported that exercise resulted in improvements in balance measures such as the timed-up-and-go, upper extremity strength, and walking velocity, as well a reduction in fall incidence and fall-related fractures.⁸² The other paper included a meta-analysis investigating the benefits of RT with or without balance exercise, and reported that exercise improved several quality-of-life domains including physical function, pain, and vitality.⁸³

Type 2 diabetes mellitus

Seven meta-analyses investigated the benefits of RT and or AT in people with type 2 diabetes with AMSTAR scores that ranged from 6 to 11.^{84–90} Aerobic exercise improved VO_2 max as evidenced by two SRs with AMSTAR scores of 6 and 11.^{84,89} Two SRs with AMSTAR scores of 6 also demonstrated reductions in SBP and DBP after AT, RT, or a combination of AT and RT.^{85,88} Strength measures improved after RT, as described by one SR with an AMSTAR of 7.⁸⁶ Glycosylated hemoglobin (HbA_{1c}), a measure of blood sugar levels, was the most consistent outcome reported in all of the included SRs, with a reduction in this seen in all reviews regardless of the type of exercise training.^{84–90}

The exercise interventions described were quite varied across the SRs. AT consisted of stationary cycling, outdoor cycling, walking, jogging, swimming, rowing, or skiing. RT was performed using a Theraband, free weights, or weight machines. AT intensity ranged 50%–85% of VO_2 max, 35%–85% of HRmax, or 40%–80% of HRR. RT intensity ranged 50%–85% of one RM. The exercise sessions were between 30 and 120 minutes, and the duration of the program ranged from 5 to 52 weeks. The SRs primarily focused on the benefits of AT, RT, or a combination of these interventions. However, no studies focused on balance or functional training, or reported functional or quality-of-life outcomes.

HIV/AIDS

Interval and continuous AT improved VO_2 max in patients living with HIV, as evidenced by a Cochrane review with an AMSTAR score of 10.⁹¹ This SR also described improved strength in five of the six studies that reported this measure. Additional benefits from exercise training include no change in the viral load, an increase in CD4 cell counts after interval AT, and improved Profile of Moods scores after AT. A summary of the interventions applied is shown in Table 3.

Depression

The five SRs relating to depression were moderate-to-high quality (AMSTAR 8-11).⁹²⁻⁹⁶ Exercise programs (AT, RT, or a combination of these) for people diagnosed with major or minor depression were found to result in improved scores on depression and mood, particularly in the short term.^{92,93} Medium- to long-term effects were less clear.^{92,93} As a group of studies, the interventions were not well described. Most examined both AT, RT, and mixed AT plus RT, except one⁹² that focused on AT. The intensity of AT, if described, was moderate to high.^{93,95} Each session was 30 to 60 minutes in length, with these performed one to five times per week, and the duration of the programs was between 10 days and 52 weeks.

Discussion

This synthesis examined 58 systematic reviews of exercise training in people with AECOPD, COPD, or eleven chronic conditions commonly associated with COPD. Overall, this review provides Level 1A evidence⁹⁷ that exercise training improves generic or disease-specific measures of fitness in several disease populations. Markers of endurance (aerobic capacity, 6MWD) were shown to improve in all conditions except depression, whereas strength was shown to improve in most conditions with the exception of PVD, hypertension,

obesity, and depression. In addition, several studies in different disease populations also reported improvements in quality of life, function, control, or prevention outcomes. Depression was the only condition where SRs exclusively focused on disease-specific outcomes (measures of depression and anxiety).⁹²⁻⁹⁶ Exercise training also decreases the risk of mortality in older adults,⁵⁰ and in those with COPD³⁹ or ischemic heart disease.⁶⁶

Overwhelmingly, the most common types of training provided to people with all conditions reviewed were AT and RT. Balance and functional training were less commonly applied SRs of exercise training. However, these interventions had widespread application in most SRs that examined older adults,^{46-49,51,52} and in one SR that examined OA patients⁷⁹ and one that examined osteoporosis patients.⁸²

The quality of the SRs for most conditions was moderate to excellent (>65%) as evaluated by AMSTAR scores. However, SRs that examined training outcomes in heart failure, ischemic heart disease, hypertension, and osteoporosis scored moderately poorly on the AMSTAR ($\geq 51\%$ but $\leq 61\%$). The listing of articles that were excluded from in the review was the most common item omitted from most SRs, which may have been due to page constraints. Even with this item excluded, the AMSTAR scores remained relatively low for heart failure (56%) whereas scores for the other conditions were $\geq 66\%$. In addition to the SR design and strength of AMSTAR scores, the number of participants and RCTs for each condition, including COPD, were large. These numbers further strengthen the foundation of evidence and recommendations for exercise training as an intervention that produces positive outcomes for COPD and commonly associated conditions.⁹⁸

Although COPD patients often have one or more comorbidities, no information is available, on prescription parameters of exercise training for patients with multimorbidity. Training parameters from studies examining conditions that are common comorbidities might be applicable, however, consideration should be given to similarities of patient demographics and details of training, especially intensity. Given that the most common conditions associated with COPD are obesity (prevalence of 54%),²⁶ osteoporosis (60%–70%)²³ and osteoarthritis (increasing prevalence to 40% at age 75)²⁷ (see Table 1), data from SRs describing these conditions may have the greatest relevance. The pertinence of these data is further strengthened by the similarity in age of participants from SRs that examined exercise training in people who were obese, had osteoporosis or osteoarthritis to those affected by COPD. In contrast, subjects were somewhat younger in

some of the RCTs that examined obesity. Gender was mixed in all of these conditions, except in the case of the SRs on osteoporosis in which predominantly women were studied.^{82,83}

The modalities of AT and RT for obesity, osteoporosis, and osteoarthritis were similar to those typically applied for COPD patients, although exercise training for these conditions utilized more diverse types of training. The intensity of AT appeared to be much higher for obese individuals and those with arthritis compared to that prescribed for COPD patients; intensity was commonly based on aerobic or HR parameters for the former compared to walk distance or dyspnea measures used in COPD patients. This raises the notion that a broader spectrum approach to exercise training in order to improve fitness in patients with COPD and comorbidities such as obesity, osteoporosis, and osteoarthritis may be effective. However, exercise training of the more complex COPD patient (with multiple comorbidities) may result in smaller gains of disease-specific outcomes due to the inability to achieve comparable AT and RT intensities (compared to those achieved in patients with a single condition). These issues merit further study.

Because obesity is a major cause of morbidity and a significant risk factor for other comorbidities such as heart disease and diabetes,^{26,75,76} SRs addressing exercise fitness outcomes other than body composition are needed in order to determine the overall impact of exercise training in this particular group. Although altering body composition may be the primary outcome for people who are obese, understanding the training and physiologic determinants to achieve that goal are essential; thus fitness outcomes such as aerobic capacity and strength measures should be reported in order to better evaluate the type and intensity of training that results in improvement. Moreover, it has also recently been demonstrated that some obese COPD patients have better fitness outcomes than non-obese COPD patients.⁹⁹ Determining how physical activity interventions can attenuate obesity, reduce cardiovascular risk factors, and improve overall fitness in people with COPD needs further attention.

Depression is a common comorbidity in COPD with estimates of prevalence ranging between 10% and 80%.²⁵ SRs that examined the effect of exercise on depression had participants with an age range similar to those with COPD, and the interventions were similar to many of the other conditions in this review. A major contrast to the other SRs was that only disease-specific outcomes and no generic fitness measures were reported. All five SRs demonstrated significant decreases in depression or anxiety scores.⁹²⁻⁹⁶ These benefits were reported regardless of whether AT, RT, or a combination

of AT and RT were applied. Of interest is the finding that the benefits decreased in response to longer training programs. More RCTs are needed to examine clinical sub-groups (minor, moderate, major depression), to compare different forms of exercise, and to clarify the appropriate dose/intensity of physical exercise in addition to the mechanism of improvement. Designing a training program that might result in gains related to self-efficacy would be very different from a regimen that requires improved aerobic fitness or an endorphin response to induce a therapeutic benefit. A better understanding of the type of depression most commonly experienced by COPD will also provide further insight into if and how exercise training can reduce the clinical severity of these two conditions.

Exercise training for older adults showed the greatest contrasts to interventions applied to COPD and other associated conditions in this review. This is especially important given that many individuals with COPD who present for health care interventions are 65 or older. Major foci appeared to be on balance and functional training rather than predetermined intensities of AT or RT.^{46-49,51,52} In addition, frequently reported outcomes by the SRs on the elderly included balance/falls, and physical performance measures that were functional (ie, timed up-and-go, stair climbing) as opposed to more physiologic measures of strength and endurance. Exercise training for older adults may provide an excellent model to further broaden exercise prescription for COPD patients because, as with the elderly,^{48,49} people with COPD have a high relative risk of falls.¹⁰⁰ In addition, the physical activity level of COPD patients is often comparable to much older, healthier adults. Thus, a greater focus on balance and functional training may not only reduce falls in COPD patients but might also result in greater gains in daily physical activity outside of pulmonary rehabilitation.¹⁰¹

Limitations

Although this synthesis of systematic reviews examined several conditions commonly associated with COPD, the participants within each of the SRs most often had a homogeneous presentation of the condition of interest. Only SRs of the elderly appeared to include participants with diverse and multiple morbidities. For this reason, it might be challenging to apply modalities in a sufficient dose in order to induce both generic and disease-specific benefits that address a complex patient with COPD and multimorbidities. The more functional approach of physical activity training, even in the frail elderly, did result in functional gains, and this approach may also prove to be beneficial to the AECOPD patients with multimorbidities.

Many SRs included lengthy training programs but did not compare the benefits of shorter versus longer programs, with the exception of SRs that evaluated those with hypertension^{72,74} and depression.^{92,93} These SRs indicated a slightly diminished response with longer training programs, which may have resulted in a blunting of the physiologic benefits of exercise, decreased adherence to the exercise training program, or a continued onslaught of inciting factors that could no longer be countered by the benefits of exercise training.

Conclusions

In summary, this systematic review showed evidence of significant benefits from exercise training in AECOPD, COPD, and many conditions that are common comorbidities associated with COPD. Exercise training, primarily consisting of AT and/or RT, leads to meaningful generic and disease-specific benefits in these conditions. Meta-analyses of endurance (aerobic or exercise capacity, 6MWD) were shown to improve in most conditions whereas meta-analyses of strength were shown to improve in five of the 13 conditions (that is, COPD, older adults, heart failure, ischemic heart disease, and diabetes). Additional research is required to determine the added benefit of RT plus AT in several conditions that are common comorbidities associated with COPD.

A broader approach to exercise and activity prescription in pulmonary rehabilitation for AECOPD may induce therapeutic benefits to ameliorate clinical sequelae associated with COPD and comorbidities. For example, BT and functional training, similar to that applied in older adults, could potentially be very effective in improving functional outcomes including fall risk, and may have a greater impact on daily physical activity than recently demonstrated.¹⁰¹

Disclosure

The authors report no conflicts of interest in this work.

References

- World Health Organization. Programmes and projects: *Chronic Respiratory Diseases: Burden of COPD* Web page. Geneva, Switzerland: World Health Organization; 2011. Available from: <http://www.who.int/respiratory/copd/burden/en/index.html>. Accessed October 5, 2011.
- de Melo MN, Ernst P, Suissa S. Rates and patterns of chronic obstructive pulmonary disease exacerbations. *Can Respir J*. 2004;11(8):559–564.
- Vestbo J. Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. *Proc Am Thorac Soc*. 2006;3(3):252–256.
- Fitzgerald JM, Haddon JM, Bradley-Kennedy C, Kuramoto L, Ford GT; RUSIC Study Group. Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. *Can Respir J*. 2007;14(3):145–152.
- Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. *Respir Med*. 2008;102(3):413–421.
- Sin DD, Tu JV. Are elderly patients with obstructive airway disease being prematurely discharged? *Am J Respir Crit Care Med*. 2000;161(5):1513–1517.
- Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. *Thorax*. 2003;58(9):752–756.
- Gillick MR, Serrell NA, Gillick LS. Adverse consequences of hospitalization in the elderly. *Soc Sci Med*. 1982;16(10):1033–1038.
- Hirsch CH, Sommers L, Olsen A, Mullen L, Winograd CH. The natural history of functional morbidity in hospitalized older patients. *J Am Geriatr Soc*. 1990;38(12):1296–1303.
- Inouye SK, Wagner DR, Acampora D, Horwitz RI, Cooney LM Jr, Tinetti ME. A controlled trial of a nursing-centered intervention in hospitalized elderly medical patients: the Yale Geriatric Care Program. *J Am Geriatr Soc*. 1993;41(12):1353–1360.
- Sager MA, Franke T, Inouye SK, et al. Functional outcomes of acute medical illness and hospitalization in older persons. *Arch Intern Med*. 1996;156(6):645–652.
- Mahoney JE, Sager MA, Jalaluddin M. New walking dependence associated with hospitalization for acute medical illness: incidence and significance. *J Gerontol A Biol Sci Med Sci*. 1998;53A(4):M307–M312.
- Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. *Chest*. 2006;129(3):536–544.
- World Health Organization. *Facing the Facts: The Impact of Chronic Disease in Canada*. Geneva, Switzerland: World Health Organization; 2011. Available from: http://www.who.int/chp/chronic_disease_report/media/CANADA.pdf. Accessed November 21, 2011.
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004;27(5):1047–1053.
- World Diabetes Foundation. Diabetes Facts. Web page. Gentofte, Denmark: World Diabetes Foundation [updated May 5, 2011]. Available from: <http://www.worlddiabetesfoundation.org/composite-35.htm>. Accessed October 6, 2011.
- Young AS, Klap R, Shoai R, Wells KB. Persistent depression and anxiety in the United States: prevalence and quality of care. *Psychiatr Serv*. 2008;59(12):1391–1398.
- Tu K, Chen Z, Lipscombe LL, Canadian Hypertension Education Program Outcomes Research Taskforce. Prevalence and incidence of hypertension from 1995–2005: a population-based study. *CMAJ*. 2008;178(11):1429–1435.
- Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. *JAMA*. 2003;290(2):199–206.
- Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. *Circulation*. 2004;110(6):738–743.
- International Osteoporosis Foundation. *Facts and Statistics about Osteoporosis and its Impact*. Available from: <http://www.iofbonehealth.org/facts-and-statistics.html#factsheet-category-23>. Accessed February 29, 2012.
- Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*. 1993;88(1):107–115.
- Kopec JA, Rahman MM, Berthelot JM, et al. Descriptive epidemiology of osteoarthritis in British Columbia, Canada. *J Rheumatol*. 2007;34(2):386–393.
- Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? *Eur J Heart Fail*. 2006;8(7):706–711.

25. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J*. 2009;33(5):1165–1185.
26. Eisner MD, Blanc PD, Sidney S, et al. Body composition and functional limitation in COPD. *Respir Res*. 2007;8:7
27. Ferguson GT, Claverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health Study. *Chest*. 2009;136(6):1456–1465.
28. Smidt N, de Vet HC, Bouter LM, et al. Effectiveness of exercise therapy: a best-evidence summary of systematic reviews. *Aust J Physiother*. 2005;51(2):71–85.
29. Kujala UM. Evidence on the effects of exercise therapy in the treatment of chronic disease. *Br J Sports Med*. 2009;43(8):550–555.
30. American College of Sports Medicine. *ACSM's Guidelines for Exercise Testing and Prescription*. 8th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2009.
31. Canadian Society for Exercise Physiology. *Canadian Physical Activity Guidelines: Clinical Practice Guideline Development Report*. Ottawa, Canada: Canadian Society for Exercise Physiology; 2011. Available from: http://www.csep.ca/CMFiles/Guidelines/CPAGuideline_Report_JAN2011.pdf. Accessed October 14, 2011.
32. Lemmens V, Oenema A, Knut IK, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. *Eur J Cancer Prev*. 2008;17(6):535–544.
33. Ernst E. A systematic review of systematic reviews of homeopathy. *Br J Clin Pharmacol*. 2002;54(6):577–582.
34. Kujala UM. Evidence for exercise therapy in the treatment of chronic disease based on at least three randomized controlled trials – summary of published systematic reviews. *Scand J Med Sci Sports*. 2004;14(6):339–345.
35. Greaves CJ, Sheppard KE, Abraham C, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. *BMC Public Health*. 2011;11:119.
36. Taylor NF, Dodd KJ, Damiano DL. Progressive resistance exercise in physical therapy: a summary of systematic reviews. *Phys Ther*. 2005;85(11):1208–1223.
37. The Cochrane Collaboration. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 [updated March 2011]. Higgins JPT, Green S, editors. Available from: <http://www.cochrane-handbook.org/>. Accessed February 29, 2012.
38. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol*. 2009;62(10):1013–1020.
39. Puhan MA, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2009;(1):CD005305.
40. Chavannes N, Vollenberg JJ, van Schayck CP, Wouters EF. Effects of physical activity in mild to moderate COPD: a systematic review. *Br J Gen Pract*. 2002;52(480):574–578.
41. Janaudis-Ferreira T, Hill K, Goldstein R, Wadell K, Brooks D. Arm exercise training in patients with chronic obstructive pulmonary disease: as systematic review. *J Cardiopulm Rehabil Prev*. 2009;29(5):277–283.
42. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2006;(4):CD003793.
43. O'Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: a systematic review. *Chest*. 2009;136(5):1269–1283.
44. Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. *J Gen Intern Med*. 2003;18(3):213–221.
45. Vieira DS, Maltais F, Bourbeau J. Home-based pulmonary rehabilitation in chronic obstructive pulmonary disease patients. *Curr Opin Pulm Med*. 2010;16(2):134–143.
46. Chin A Paw MJ, van Uffelen JG, Riphagen I, van Mechelen W. The functional effects of physical exercise training in frail older people: a systematic review. *Sports Med*. 2008;38(9):781–793.
47. Forster A, Lambley R, Young JB. Is physical rehabilitation for older people in long-term care effective? Findings from a systematic review. *Age Ageing*. 2010;39(2):169–175.
48. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. *Cochrane Database Syst Rev*. 2003;(4):CD000340.
49. Howe TE, Rochester L, Jackson A, Banks PM, Blair VA. Exercise for improving balance in older people. *Cochrane Database Syst Rev*. 2008;(4):CD004963.
50. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. *Cochrane Database Syst Rev*. 2009;(3):CD002759.
51. Rydwick E, Frändin K, Akner G. Effects of physical training on physical performance in institutionalised elderly patients (70+) with multiple diagnoses. *Age Ageing*. 2004;33(1):13–23.
52. Weening-Dijksterhuis E, de Greef MH, Scherder EJ, Slaets JP, van der Schans CP. Frail institutionalized older persons: a comprehensive review on physical exercise, physical fitness, activities of daily living, and quality-of-life. *Am J Phys Med Rehabil*. 2011;90(2):156–168.
53. Chien CL, Lee CM, Wu YW, Chen TA, Wu YT. Home-based exercise increases exercise capacity but not quality of life in people with chronic heart failure: a systematic review. *Aust J Physiother*. 2008;54(2):87–93.
54. Hwang CL, Chien CL, Wu YT. Resistance training increases 6-minute walk distance in people with chronic heart failure: a systematic review. *J Physiother*. 2010;56(2):87–96.
55. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. *Eur J Heart Fail*. 2010;12(7):706–715.
56. Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. *J Am Coll Cardiol*. 2007;49(24):2329–2336.
57. Hwang R, Marwick T. Efficacy of home-based exercise programmes for people with chronic heart failure: a meta-analysis. *Eur J Cardiovasc Prev Rehabil*. 2009;16(5):527–535.
58. van Tol BA, Huijsmans RJ, Kroon DW, Schothorst M, Kwakkel G. Effects of exercise training on cardiac performance, exercise capacity and quality of life in patients with heart failure: a meta-analysis. *Eur J Heart Fail*. 2006;8(8):841–850.
59. Benton MJ. Safety and efficacy of resistance training in patients with chronic heart failure: research-based evidence. *Prog Cardiovasc Nurs*. 2005;20(1):17–23.
60. Cahalin LP, Ferreira DC, Yamada S, Canavan PK. Review of the effects of resistance training in patients with chronic heart failure: potential effects upon the muscle hypothesis. *Cardiopulm Phys Ther J*. 2006;17(1):15–28.
61. Spruit MA, Eterman RM, Hellwig VA, Janssen PP, Wouters EF, Uszko-Lencer NH. Effects of moderate-to-high intensity resistance training in patients with chronic heart failure. *Heart*. 2009;95(17):1399–1408.
62. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. *Ann Intern Med*. 2005;143(9):659–672.
63. Cornish AK, Broadbent S, Cheema BS. Interval training for patients with coronary artery disease: a systematic review. *Eur J Appl Physiol*. 2011;111(4):579–589.
64. Cortes OL, Villar JC, Devereaux PJ, DiCenso A. Early mobilisation for patients following acute myocardial infarction: a systematic review and meta-analysis of experimental studies. *Int J Nurs Stud*. 2009;46(11):1496–1504.
65. Haykowsky M, Scott J, Esch B, et al. A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling. *Trials*. 2011;12:92.

66. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. *Cochrane Database Syst Rev*. 2009;(1):CD001800.
67. Oliveira JL, Galvão CM, Rocha SM. Resistance exercises for health promotion in coronary patients: evidence of benefits and risks. *Int J Evid Based Healthc*. 2008;6(4):431–439.
68. Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. *Scand J Med Sci Sports*. 2010;20(4):545–555.
69. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst Rev*. 2008;(4):CD000990.
70. Wind J, Koelemay MJ. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. *Eur J Vasc Endovasc Surg*. 2007;34(1):1–9.
71. Kelley GA, Kelley KA, Tran ZV. Aerobic exercise and resting blood pressure: a meta-analytic review of randomized, controlled trials. *Prev Cardiol*. 2001;4(2):73–80.
72. Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. *Hypertension*. 2005;46(4):667–675.
73. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens*. 2006;24(2):215–233.
74. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med*. 2002;136(7):493–503.
75. Witham MD, Avenell A. Interventions to achieve long-term weight loss in obese older people: a systematic review and meta-analysis. *Age Ageing*. 2010;39(2):176–184.
76. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. *Cochrane Database Syst Rev*. 2006;(4):CD003817.
77. Ottawa Panel. Evidence-based clinical practice guidelines for therapeutic exercises and manual therapy in the management of osteoarthritis. *Phys Ther*. 2005;85(9):907–971.
78. Brosseau L, Pelland L, Wells G, et al. Efficacy of aerobic exercises for osteoarthritis (part II): a meta-analysis. *Phys Ther Rev*. 2004;9(3):125–145.
79. Devos-Comby L, Cronan T, Roesch SC. Do exercise and self-management interventions benefit patients with osteoarthritis of the knee? A metaanalytic review. *J Rheumatol*. 2006;33(4):744–756.
80. Lange AK, Vanwanseele B, Fiatarone Singh MA. Strength training for treatment of osteoarthritis of the knee: a systematic review. *Arthritis Rheum*. 2008;59(10):1488–1494.
81. Pelland L, Brosseau L, Wells G, et al. Efficacy of strengthening exercises for osteoarthritis (part I): a meta-analysis. *Phys Ther Rev*. 2004;9(2):77–108.
82. de Kam D, Smulders E, Weerdesteyn V, Smits-Engelsman BC. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. *Osteoporos Int*. 2009;20(12):2111–2125.
83. Li WC, Chen YC, Yang RS, Tsauo JY. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. *Clin Rehabil*. 2009;23(10):888–896.
84. Boulé NG, Kenny GP, Haddad E, Wells GA, Sigal RJ. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus. *Diabetologia*. 2003;46(8):1071–1081.
85. Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. *Diabetes Care*. 2011;34(5):1228–1237.
86. Irvine C, Taylor NF. Progressive resistance exercise improves glycaemic control in people with type 2 diabetes mellitus: a systematic review. *Aust J Physiother*. 2009;55(4):237–246.
87. Kelley GA, Kelley KS. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. *Public Health*. 2007;121(9):643–655.
88. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. *Diabetes Care*. 2006;29(11):2518–2527.
89. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2009;(3):CD002968.
90. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA_{1c} levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305(17):1790–1799.
91. O'Brien K, Nixon S, Tynan AM, Glazier RH. Aerobic exercise interventions for people living with HIV/AIDS: implications for practice, education, and research. *Physiother Can*. 2006;58(2):114–129.
92. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. *BMJ*. 2001;322(7289):763–767.
93. Krogh J, Nordentoft M, Sterne JA, Lawlor DA. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. *J Clin Psychiatry*. 2011;72(4):529–538.
94. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. *Arch Intern Med*. 2010;170(4):321–331.
95. Rethorst CD, Wipfli BM, Landers DM. The antidepressive effects of exercise: a meta-analysis of randomized trials. *Sports Med*. 2009;39(6):491–511.
96. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. *Cochrane Database Syst Rev*. 2008;(4):CD004366.
97. Centre for Evidence Based Medicine. Levels of Evidence. EBM Tools. Available at <http://www.cebm.net/index.aspx?o=1025>. Accessed February 29, 2012.
98. Marciniuk DD, Brooks D, Butcher S, et al. Optimizing pulmonary rehabilitation in COPD – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. *Can Respir J*. 2010;17(4):159–168.
99. Ora J, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O'Donnell DE. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. *Am J Respir Crit Care Med*. 2009;180(10):964–971.
100. Roig M, Eng JJ, MacIntyre DL, et al. Falls in people with chronic obstructive pulmonary disease: an observational cohort study. *Resp Med*. 2011;105(3):461–469.
101. Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R. Are patients with COPD more active after pulmonary rehabilitation? *Chest*. 2008;134(2):273–280.

Appendix I

Search strategy for Medline Ovid

Most of the numbered items are entered as keywords or phrases in the search box on the main page of Medline OvidSP. However, some line items at the end of each concept (eg, line 7) are commands to combine previous items in a particular fashion for the main concept. Asterisks indicate truncated terms in Medline. As well, abbreviations (ie, adj3) can be used to link words together.

Similar search terms were used in all databases. However, the preferred term could differ and the user needed to determine if the alternate term provided in a database was suitable. In addition, the manner of truncation, labeling for title or abstract, and combining of terms differed amongst databases.

Concept: COPD

1. lung diseases, obstructive/or exp pulmonary disease, chronic obstructive/or bronchitis, chronic/
2. exp Pulmonary Emphysema/
3. (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).ti,ab.
4. ((chronic airflow or chronic airway*) adj2 (disease* or disorder* or obstruct* or limitation*)).ti,ab.
5. (COPD or COAD or chronic bronchi* or emphysema* or hyperlucent lung*).ti,ab.
6. (chronic adj3 obstructive).ti,ab.
7. or/1–6

Concept: comorbidities

8. bronchial diseases/or asthma/or bronchial hyperreactivity/ or bronchial spasm/or bronchiectasis/or exp bronchitis/ or bronchopneumonia/
9. (bronchial disease* or asthma* or bronchial asthma* or bronchial hyperreactivit* or bronchospasm*).ti,ab.
10. (bronchiectas* or bronchitis or bronchopneumonia* or bronchial pneumonia*).ti,ab.
11. exp Pneumonia/
12. (pneumonia* or pneumoniti* or pulmonary inflammation* or lung inflammation* or lobar pneumonia*).ti,ab.
13. Influenza, Human/
14. ((influenza adj3 human*) or human flu or influenza* or grippe).ti,ab.
15. respiratory insufficiency/
16. (respiratory insufficiency or respiratory failure or respiratory depression).ti,ab.

17. heart diseases/or arrhythmias, cardiac/or heart failure/ or myocardial ischemia/or myocardial infarction/or pulmonary heart disease/
18. (arrhythmia or arrhythmia or cardiac arrhythmia* or cardiac dysrhythmia*).ti,ab.
19. (heart failure or cardiac failure or myocardial failure or heart decompensation or myocardial infarction).ti,ab.
20. (pulmonary heart disease* or cor pulmonale).ti,ab.
21. Hypertension/
22. (hypertension or high blood pressure).ti,ab.
23. Diabetes Mellitus/
24. (diabetes mellitus or diabetes).ti,ab.
25. Obesity/or Overweight/
26. (obesity or overweight).ti,ab.
27. Sleep Apnea, Obstructive/
28. (sleep apnea or obstructive sleep apnea or obstructive sleep apnea syndrome).ti,ab.
29. Depression/
30. (depression* or depressive symptoms or emotional depression*).ti,ab.
31. Anxiety/
32. (anxiet* or nervousness or anxious).ti,ab.
33. Anemia/
34. (anemia* or anaemia).ti,ab.
35. Osteoporosis/
36. (osteoporos#s or senile osteoporos#s or bone-loss*).ti,ab.
37. Osteoarthritis/
38. (osteoarthritis or osteoarthritis or osteoarthros#s or degenerative arthritis).ti,ab.
39. osteopenia.mp.
40. exp aged/or frail elderly/
41. (aged or elderly or frail elderly or frail elder* or frail older adult*).ti,ab.
42. or/8–41
43. 7 or 42

Concept: hospitalized patients

44. exp Inpatients/
45. Hospitalization/
46. (inpatient* or in-patient* or hospitalized or hospitalised or hospitalization*).ti,ab.
47. or/44–46
48. 43 and 47

Concept: exercise

49. exp exercise/or exp walking/
50. exp Exercise Therapy/

51. Physical Fitness/
52. Exercise Movement Techniques/
53. (exercise* or physical exercise* or exercise therap* or walk* or ambulat* or physical fitness or physical activity).ti,ab.
54. (exercise* adj5 train*).mp.
55. (strength* adj5 train*).mp.
56. exp "Physical Therapy (Specialty)"/
57. (physiother* or physical therap*).mp.
58. Rehabilitation/
59. rehabilitat*.mp.
60. or/49–59
61. 48 and 60
62. animals/not humans/
63. 61 not 62
64. limit 63 to English

International Journal of COPD

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-copd-journal>

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.